Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 Combined With Penpulimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT05563480Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2022
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2618 in nasopharyngeal carcinoma (NPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Oct 2022; status: completed.
02
Drugs
TQB2618
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05563480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563480.